和元生物(688238.SH):將進一步加速國際化進程
格隆匯4月24日丨有投資者向和元生物(688238.SH)提問:公司對海外業務是否有明確的發展戰略與業務指標?
和元生物回覆:公司堅持國際化發展戰略和思路,以國內基因治療市場為起點,基於基因治療藥物中、美、澳IND申報項目經驗,逐步將業務拓展至全球主要的生物製藥核心市場。公司將進一步加速國際化進程,目前美國子公司已經完成首期投資所涉境外投資項目相關備案手續,正在積極搭建研發實驗室,組建具有全球化視野及國際競爭力的人才隊伍,逐步建設本地化運營;同時,着力提升公司海外品牌知名度,加大市場宣傳影響力,積極開拓國際客户及訂單。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.